Dechra Pharmaceuticals plc (LON:DPH) announced a dividend on Monday, September 4th, Upcoming.Co.Uk reports. Stockholders of record on Thursday, October 26th will be paid a dividend of GBX 15.33 ($0.20) per share on Friday, November 17th. This represents a dividend yield of 0.74%. The ex-dividend date is Thursday, October 26th. This is an increase from Dechra Pharmaceuticals plc’s previous dividend of $6.11. The official announcement can be viewed at this link.

Shares of Dechra Pharmaceuticals plc (LON DPH) opened at 2050.00 on Friday. Dechra Pharmaceuticals plc has a one year low of GBX 1,225.00 and a one year high of GBX 2,185.00. The stock’s 50 day moving average price is GBX 2,057.32 and its 200 day moving average price is GBX 1,846.08. The company’s market cap is GBX 1.91 billion.

In other Dechra Pharmaceuticals plc news, insider Ian Page sold 54,910 shares of the company’s stock in a transaction dated Tuesday, September 19th. The stock was sold at an average price of GBX 2,024 ($26.89), for a total value of £1,111,378.40 ($1,476,718.58).

ILLEGAL ACTIVITY WARNING: “Dechra Pharmaceuticals plc (DPH) Raises Dividend to GBX 15.33 Per Share” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/21/dechra-pharmaceuticals-plc-dph-raises-dividend-to-gbx-15-33-per-share.html.

A number of equities research analysts recently weighed in on DPH shares. Jefferies Group LLC boosted their price objective on Dechra Pharmaceuticals plc from GBX 1,565 ($20.79) to GBX 1,868 ($24.82) and gave the stock a “hold” rating in a research report on Tuesday, September 5th. Stifel Nicolaus restated a “hold” rating and set a GBX 1,550 ($20.60) price objective on shares of Dechra Pharmaceuticals plc in a research report on Tuesday, July 11th. Investec restated a “buy” rating and set a GBX 1,840 ($24.45) price objective on shares of Dechra Pharmaceuticals plc in a research report on Thursday, July 6th. Numis Securities Ltd restated an “add” rating and set a GBX 1,890 ($25.11) price objective on shares of Dechra Pharmaceuticals plc in a research report on Thursday, July 6th. Finally, N+1 Singer restated a “buy” rating and set a GBX 1,666 ($22.14) price objective on shares of Dechra Pharmaceuticals plc in a research report on Thursday, July 6th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of GBX 1,784 ($23.70).

About Dechra Pharmaceuticals plc

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.

Dividend History for Dechra Pharmaceuticals plc (LON:DPH)

Receive News & Stock Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related stocks with our FREE daily email newsletter.